Oxford Biomedica Logo
Scientist microscope

Press releases 2008

Date Headline
19/11/08 Oxford BioMedica Announces Six-Month Efficacy Results with Low Dose of ProSavin® in Phase I/II Trial in Parkinson's Disease
18/11/08 Oxford BioMedica plc Interim Management Statement
14/11/08 Oxford BioMedica Announces Two Scientific Presentations of ProSavin® in Parkinson's Disease
07/11/08 Oxford BioMedica to Present at Rodman & Renshaw 10th Annual Healthcare Conference
24/10/08 Oxford BioMedica Reports Data on Association between Immune Response And Patient Survival from TroVax® Trials in Colorectal, Renal and Prostate Cancer
13/10/08 Oxford BioMedica Announces Appointment of John Dawson as Chief Executive Officer
07/10/08 Oxford BioMedica Announces FDA Agreement on Revisions for Ongoing TroVax® Phase III TRIST Study
18/09/08 Oxford BioMedica to Present at UBS Global Life Sciences Conference
09/09/08 Oxford BioMedica Announces Promising Interim Phase I/II Results of ProSavin® in Parkinson's Disease
29/08/08 Oxford BioMedica plc Unaudited Interim Results for the Six Months Ended 30 June 2008
29/08/08 Oxford BioMedica Announces Board Changes
27/08/08 Oxford BioMedica plc Notice of Interim Results for the Six Months Ended 30 June 2008
15/08/08 Oxford BioMedica confirms Rejection of GeneThera's Indicative Approach
28/07/08 Oxford BioMedica Appoints John Dawson as Non-Executive Director
15/07/08 Oxford BioMedica Reports Further Data from Interim Review of TroVax® Phase III Trist Study
14/07/08 Oxford BioMedica Receives Commitment For Independent Phase III Trial Of TroVax® In Adjuvant Colorectal Cancer
01/07/08 Oxford BioMedica Announces Data Safety Monitoring Board Recommendation for TroVax® Phase III Trist Study
01/07/08 Oxford BioMedica Response to Bavarian Nordic's US Litigation
24/06/08 Oxford BioMedica to Present at Jefferies Healthcare Conference
02/06/08 Sanofi-Aventis and Oxford BioMedica report encouraging TroVax® Phase II Trial results in metastatic renal cancer
19/05/08 Oxford BioMedica to Present at Rodman & Renshaw Healthcare Conference
16/05/08 Oxford BioMedica Announces TroVax® Phase II Trial Results in Renal Cancer to be Presented at ASCO
09/05/08 Oxford BioMedica Annual General Meeting
09/05/08 Oxford BioMedica Interim Management Statement
01/05/08 Oxford BioMedica to Present at FBR Capital Markets Spring Investor Conference
21/04/08 Notice of Annual General Meeting
15/04/08 Oxford BioMedica Announces Board Changes
25/03/08 Oxford BioMedica Report Encouraging New Phase II Trial Results with TroVax® in Prostate Cancer
17/03/08 Oxford BioMedica to present at Cowen and Company Health Care Conference
10/03/08 Oxford BioMedica Appoints Dr Alex Lewis as Non-Executive Director
10/03/08 Oxford BioMedica Completes Patient Recruitment for Phase III TRIST study of TroVax® in Renal Cancer
10/03/08 Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2007
20/02/08 Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax® Phase II Trist Study Achievement Triggers €10 Million Milestone Payment from Sanofi-Aventis
07/02/08 Oxford BioMedica: Notice of FY2007 Preliminary Results
22/01/08 Oxford BioMedica Announces Development Milestone in its Collaboration with MolMed
07/01/08 Oxford BioMedica Secures Exclusive Licence to Key Intellectual Property for RNA Interference Gene Silencing Using LentiVector® Technology